Render Target: STATIC
Render Timestamp: 2024-11-20T10:38:47.630Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-06-21 20:07:11.486
Product last modified at: 2024-09-27T21:15:07.546Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

HER2 (Trastuzumab Biosimilar) Human mAb #10583

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG1 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    HER2 (Trastuzumab Biosimilar) Human mAb is a biosimilar antibody for Trastuzumab. Trastuzumab is a therapeutic human monoclonal antibody directed against human HER2 used to treat HER2-positive breast cancer.
    Endotoxin <0.1 EU/μg of antibody

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free.

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    HER2 (Trastuzumab Biosimilar) Human mAb was confirmed to bind to its intended target protein HER2 using flow cytometry.

    Species Reactivity:

    Human

    Source / Purification

    HER2 (Trastuzumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Trastuzumab is an antibody directed against the extracellular region of human HER2.

    Background

    The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.